Table 1 Characteristics for nasopharyngeal carcinoma patients stratified by surgery and radiation treatment
Covariate | Level | Overall (n = 3919) | Surgery | Radiation | ||||
|---|---|---|---|---|---|---|---|---|
Performed (n = 398) | None or refused (n = 3480) | p value | Radiation (n = 3114) | None or Refused (n = 657) | p value | |||
Age | 53.64 ± 15.26 54 (44, 63) | 52.03 ± 16.43 53 (42, 63) | 53.79 ± 15.08 54 (45, 63) | 0.04 | 52.54 ± 14.87 53 (44,62) | 58.40 ± 15.95 58 (49, 69) | <0.0001 | |
Survival months | 36.97 ± 32.47 27 (9, 59) | 43.34 ± 32.56 38.5 (15, 64) | 36.24 ± 32.37 26 (9, 58) | <0.0001 | 40.17 ± 32.49 31 (12, 62) | 22.67 ± 28.58 10 (2, 32) | <0.0001 | |
All-cause mortality | No | 2471 (63.05%) | 284 (71.36%) | 2169 (62.33%) | 0.0004 | 2125 (68.24%) | 267 (40.64%) | <0.0001 |
Yes | 1448 (36.95%) | 114 (28.64%) | 1311 (37.67%) | 989 (31.76%) | 390 (59.36%) | |||
NPC-specific death | No | 2471 (74.97%) | 284 (82.08%) | 2169 (74.36%) | 0.002 | 2125 (79.06%) | 267 (54.83%) | <0.0001 |
Yes | 825 (25.03%) | 62 (17.92%) | 748 (25.64%) | 563 (20.94%) | 220 (45.17%) | |||
Sex | Male | 2798 (71.40%) | 271 (68.09%) | 2502 (71.90%) | 0.11 | 2214 (71.10%) | 473 (71.99%) | 0.64 |
Female | 1121 (28.60%) | 127 (31.91%) | 978 (28.10%) | 900 (28.90%) | 184 (28.01%) | |||
Race | White | 1784 (48.58%) | 233 (61.64%) | 1528 (46.96%) | <0.0001 | 1387 (47.35%) | 332 (54.52%) | 0.0009 |
Black | 448 (12.20%) | 50 (13.23%) | 393 (12.08%) | 351 (11.98%) | 82 (13.46%) | |||
Chinese | 669 (18.22%) | 32 (8.47%) | 631 (19.39%) | 559 (19.09%) | 85 (13.96%) | |||
Other Asian | 771 (21.00%) | 63 (16.67%) | 702 (21.67%) | 632 (21.58%) | 110 (18.06%) | |||
Grade | Well-differentiated | 61 (2.23%) | 13 (4.15%) | 46 (1.91%) | 0.04 | 46 (2.04%) | 13 (3.19%) | <0.0001 |
Moderate | 359 (13.11%) | 48 (15.34%) | 307 (12.77%) | 261 (11.58%) | 78 (19.12%) | |||
Poorly differentiated | 1256 (45.87%) | 135 (43.13%) | 1113 (46.30%) | 1037 (46.01%) | 190 (46.57%) | |||
Undifferentiated | 1062 (38.79%) | 117 (37.38%) | 938 (39.02%) | 910 (40.37%) | 127 (31.13%) | |||
Histology | Keratinizing | 184 (16.93%) | 21 (17.21%) | 162 (16.88%) | 0.93 | 139 (15.48%) | 41 (28.28%) | 0.0002 |
Non-keratinizing | 903 (83.07%) | 101 (82.79%) | 798 (83.13%) | 759 (84.52%) | 104 (71.72%) | |||
T-stage | T0 | 31 (0.89%) | 4 (1.10%) | 27 (0.87%) | 0.003 | 25 (0.86%) | 4 (0.88%) | 0.01 |
T1 | 1126 (32.38%) | 150 (41.10%) | 971 (31.42%) | 945 (32.44%) | 140 (30.70%) | |||
T2 | 786 (22.61%) | 81 (22.19%) | 699 (22.62%) | 692 (23.76%) | 80 (17.54%) | |||
T3 | 729 (20.97%) | 61 (16.71%) | 662 (21.42%) | 597 (20.49%) | 110 (24.12%) | |||
T4 | 805 (23.15%) | 69 (18.90%) | 731 (23.66%) | 654 (22.45%) | 122 (26.75%) | |||
N-stage | N0 | 856 (23.72%) | 141 (38.42%) | 708 (21.97%) | <0.0001 | 663 (22.19%) | 166 (32.74%) | <0.0001 |
N1 | 1270 (35.19%) | 127 (34.60%) | 1137 (35.29%) | 1052 (35.21%) | 177 (34.91%) | |||
N2 | 997 (27.63%) | 72 (19.62%) | 920 (28.55%) | 874 (29.25%) | 93 (18.34%) | |||
N3 | 286 (13.47%) | 27 (7.36%) | 457 (14.18%) | 399 (13.35%) | 71 (14.00%) | |||
M-stage | M0 | 3261 (88.98%) | 346 (95.05%) | 2889 (88.32%) | <0.0001 | 2748 (91.63%) | 408 (74.59%) | <0.0001 |
M1 | 404 (11.02%) | 18 (4.95%) | 382 (11.68%) | 251 (8.37%) | 139 (25.41%) | |||
AJCC stage | I | 292 (8.51%) | 65 (18.52%) | 224 (7.32%) | <0.0001 | 229 (7.98%) | 57 (12.39%) | <0.0001 |
II | 741 (21.60%) | 92 (26.21%) | 647 (21.14%) | 662 (23.06%) | 58 (12.61%) | |||
III | 969 (28.24%) | 85 (24.22%) | 879 (28.73%) | 859 (29.92%) | 87 (18.93%) | |||
IV | 1429 (41.65%) | 109 (31.05%) | 1310 (42.81%) | 1121 (39.05%) | 258 (56.09%) | |||
Radiation | No | 657 (17.42%) | 62 (16.02%) | 591 (17.57%) | 0.45 | |||
Yes | 3114 (82.58%) | 325 (83.98%) | 2772 (82.43%) | |||||
Surgery | None or refused | 3480 (89.74%) | 2772 (89.51%) | 591 (90.51%) | 0.45 | |||
Performed | 398 (10.26%) | 325 (10.49%) | 62 (9.49%) | |||||